Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Closed-loop Strategy vs Sensor-augmented Pump Therapy in Type 1 Diabetes
NCT02846857Phase 2Withdrawn
- Sponsor
- Montreal Clinical Research Institute
- Primary completion
- Jul 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of glucagon in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Montreal Clinical Research Institute. Primary endpoint: Percentage of time of glucose levels below 3.9 mmol/L at 15 weeks. Status: withdrawn.
02
Drugs
glucagon
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02846857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02846857.